Product Certification&
    Enterprise Certification

  • Mr.Xie
    Tel: +86-592-5853819

  • Ms.Serein Yan
    Region Sales Manager
    Tel: +86 0592 5887162

  • Ms.Coco Lv
    Region Sales Manager
    Tel: 0086-592-5881075

  • Ms.Penny Pan
    Region Sales Manager
    Tel: 0086-592-5881087

  • Ms.Shirley Shi
    Region Sales Manager
    Tel: +8613666090822

  • Ms.Denise Lai
    Region Sales Manager
    Tel: 0086-592-5887167

  • Mr.Duncan Deng
    Region Sales Manager
    Tel: +8617750663255

  • Ms.Susie Yan
    Region Sales Manager
    Tel: +8618060975837

  • Ms.Annette Wang
    Region Sales Manager
    Tel: +8615882299465

  • Mobile:+86 13806035118
  • Tel:+86-592-5853819
  • Fax:+86-592-5854960
  • URL:http://www.china-sinoway.com
  • Province/state:fujian
  • City:Xiamen
  • Street:16/F,Huicheng Comm,Complex,No839 XiaHe Rd, Xiamen,China
  • MaxCard:
Home > Products >  factory supply GMP,WC Sacubitril + Valsartan

factory supply GMP,WC Sacubitril + Valsartan CAS NO.936623-90-4

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,Other
  • Product Details

Keywords

  • Sacubitril + Valsartan
  • LCZ696
  • 936623-90-4

Quick Details

  • ProName: factory supply GMP,WC Sacubitril + Val...
  • CasNo: 936623-90-4
  • Molecular Formula: C15H18
  • Appearance: White crystallization
  • Application: Cardiovascular APIs,Sartan antihyperte...
  • DeliveryTime: in two weeks
  • PackAge: 25kg/drum
  • Port: SHANGHAI BEIJING
  • ProductionCapacity: 10 Metric Ton/Day
  • Purity: USP/EP/BP
  • Storage: room temperature
  • Transportation: AIR SEA TRAIN
  • LimitNum: 1 Kilogram

Superiority

We are very compeitive on Sacubitril + Valsartan.Our mfr is GMP certified for this item with WC document. 

LCZ696 , a first-in-class inhibitor of dualacting angiotensin-2 type-I receptor and neprilysin inhibitors, was developed as a molecule composed of molecular moieties of valsartan and neprilysin inhibitor prodrug AHU377 in a 1:1 ratio. Several phase 2 randomised clinical trials have been done or are underway in patients with hypertension. In a proof-of-concept randomised trial, LCZ696 was compared with valsartan in 1328 patients with mild-to-moderate hypertension, and provided fully additive reduction of blood pressure. No cases of angio-oedema were reported in the 8 week treatment period. This tolerance should be confirmed, particularly in black patients, for whom omapatrilat resulted in a higher occurrence of angio-oedema than in white patients. Indeed, in the proof-of-concept trial only about 8% of patients were black.

Details

Product Name: LCZ696
Synonyms: Sacubitril mixture with Valsartan
CAS: 936623-90-4
MF: C48H58N6O8
MW: 847.03
Product Categories: Cardiovascular Series;Inhibitors;API

 

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog